Business Wire

LobSor Pharmaceuticals and TFS report LECIGon® Achieving Its Primary Endpoint in a Pivotal EU Study for Advanced Parkinson’s Disease

· LobSor plans to submit its regulatory application for EU approval in early 2016 · LobSor in process of planning discussions with the U.S. Food and Drug Administration (FDA) to outline US path to ...
FiercePharma

Recipharm reaches agreement with LobSor Pharmaceuticals to manufacture LECIGONTM, a proprietary treatment for advanced Parkinson's disease.

Sept. 8, 2015 - Recipharm and LobSor Pharmaceuticals, an Uppsala-based pharmaceutical company focusing on the development of innovative systems to treat symptoms of advanced Parkinson's disease (APD), ...
mp.pl

Rekomendacja Prezesa AOTMiT – Lecigon

Prezes Agencji nie rekomenduje objęcie refundacją produktu leczniczego Lecigon (lewodopa + karbidopa + entakapon) w ramach programu lekowego B.90. „Leczenie zaburzeń motorycznych w przebiegu ...
Pharmabiz

Bioglan, STADA partner to increase production capacity to meet rising demand for Parkinson’s treatment

Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company REIG JOFRE, (BME:RJF), and STADA Arzneimittel AG have signed an agreement to expand the production capacity for manufacturing ...
Business Wire

Intrance Medical Systems Establishes U.S. Operations and Names Patrick Shea Chief Executive Officer

Pharmaceutical industry leader to build organization from ground up with commitment to bringing innovation to the advanced Parkinson’s disease community Company plans to initiate U.S. clinical ...